Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management

Frontiers in Allergy

Allergy

Sergio E. Chiarella¹  Thanai Pongdee¹  Andrea Sitek² 

[1] Division of Allergic Diseases, Mayo Clinic, Rochester, MN, United States;Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas, KS, United States;

关键词: hypersensitivity;    anaphylaxis;    biologic;    monoclonal antibody;    desensitization;    serum sickness;   

DOI  :  10.3389/falgy.2023.1219735

 received in 2023-05-09, accepted in 2023-08-01,  发布年份 2023

来源: Frontiers

【 摘 要 】

Several monoclonal antibodies have been approved by the Food and Drug Administration (FDA) to treat allergic disorders, including omalizumab, dupilumab, mepolizumab, reslizumab, benralizumab, tralokinumab and tezepelumab, and their indications continue to expand. Although the risks associated with these agents are overall low, hypersensitivity reactions have been described and are reported more frequently with increased use. We provide a comprehensive review of clinical features, diagnosis and management of hypersensitivity reactions attributed to these agents. We aim to provide useful information for the clinician managing hypersensitivity reactions to these monoclonal antibodies, as well as highlight the need for future research to address specific gaps in knowledge.

【 授权许可】

Unknown   
© 2023 Sitek, Chiarella and Pongdee.